Portfolio Update and Presentation

Summary by AI BETAClose X

EMV Capital plc will host a virtual investor event on July 27, 2026, to provide updates on its portfolio companies AMR Bio and ProAxsis. AMR Bio will share progress on its XF-73 asset as it moves towards Phase 3 trials, while ProAxsis will discuss its repositioning and growth in the COPD market, including a clinical study with Imperial College London. The event aims to offer investors deeper insights into these deep tech and life sciences ventures, with questions able to be submitted in advance or during the live presentation.

Disclaimer*

Companies

Emv Capital (EMVC)
UK 100

Latest directors dealings